Related Experiment Videos
ACE inhibitors and diabetic nephropathy: clinical and experimental findings
C Hasslacher1, H P Kempe, A Bostedt-Kiesel
1Abteilung Innere Medizin I, Medizinische Universitätsklinik, Heidelberg.
Abstract:
Apart from near normal metabolic control, early treatment of an increase in blood pressure in diabetic patients with nephropathy, is one of the most important therapeutic methods to prevent further progression of this complication. Long-term studies, recently published, suggest that ACE inhibitors have a beneficial effect on albuminuria and progression of nephropathy, irrespective of their hemodynamic effects. However, the mechanism by which ACE inhibitors exert these positive effects on glomerular pathology is still unclear. Several non-hemodynamic factors have been identified as being involved in the pathogenesis of diabetic nephropathy: (a) changes in the composition of glomerular basement membrane due to a changed metabolism of the proteins which make up this structure; consequences are an impairment of the filtration properties, onset of proteinuria as well as thickening of basement membrane; (b) Mesangial expansion due to an overproduction of mesangial matrix and deposition of proteins as well as (c) impairment of mesangial clearance function; consequences are development of glomerulosclerosis and reduction of filtration surface. It is known that the renin-angiotensin-system is stimulated in diabetic patients with nephropathy and that angiotensin II influences the synthesis of glomerular and mesangial proteins as well as the function of mesangial cells. Hypothetically, these points could explain the beneficial effects of ACE-inhibitors on the progression of diabetic nephropathy.
Insights
Early treatment of high blood pressure in diabetic nephropathy patients with ACE inhibitors may slow disease progression. These drugs benefit kidney health beyond blood pressure reduction, possibly by affecting non-hemodynamic factors.
Area of Science:
- Nephrology
- Diabetology
- Pharmacology
Background:
- Diabetic nephropathy management requires controlling hypertension to prevent disease progression.
- Angiotensin-Converting Enzyme (ACE) inhibitors show promise in reducing albuminuria and slowing diabetic nephropathy, independent of their blood pressure effects.
- The precise mechanisms behind ACE inhibitors' renoprotective effects in diabetic nephropathy remain unclear, prompting investigation into non-hemodynamic pathways.
Purpose of the Study:
- To explore the potential non-hemodynamic mechanisms through which ACE inhibitors exert beneficial effects on glomerular pathology in diabetic nephropathy.
- To investigate the role of the renin-angiotensin system and its influence on glomerular and mesangial cells in diabetic nephropathy.
Main Methods:
- Review of existing literature on diabetic nephropathy pathogenesis and ACE inhibitor effects.
- Analysis of non-hemodynamic factors implicated in diabetic nephropathy, including glomerular basement membrane changes, mesangial expansion, and impaired mesangial clearance.
- Examination of the stimulated renin-angiotensin system in diabetic nephropathy and the role of angiotensin II.
Main Results:
- Diabetic nephropathy involves glomerular basement membrane alterations, mesangial expansion, and impaired mesangial function, leading to proteinuria and glomerulosclerosis.
- The renin-angiotensin system is activated in diabetic nephropathy, with angiotensin II impacting glomerular and mesangial cell protein synthesis and function.
- ACE inhibitors may counteract these detrimental non-hemodynamic effects, contributing to their renoprotective benefits.
Conclusions:
- ACE inhibitors likely offer renoprotection in diabetic nephropathy through mechanisms beyond blood pressure reduction.
- Targeting non-hemodynamic pathways, such as those influenced by angiotensin II, may be crucial for managing diabetic nephropathy.
- Further research is warranted to fully elucidate the non-hemodynamic actions of ACE inhibitors in diabetic kidney disease.